ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MBOT
LNSR (18) QTEX (36) LUCD (39) SKIN (32) ⌘ Pro Terminal →

Microbot Medical Inc. (MBOT) — RQD Stock Rating Cockpit

$1.04 -4.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.03

Microbot Medical Inc. (MBOT) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $73.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MBOT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Microbot Medical Inc. (NASDAQ: MBOT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.04 (-4.59% 1D, market cap $73.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MBOT ranks #838 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MBOT compare to LNSR and QTEX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, LNSR (LENSAR Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $71.7M) and QTEX (QTREX Quantum Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MBOT?
▼

Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $41.3M in revenue (+26.8% YoY), -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.03 (-1.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (5)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE MBOT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBOT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY MBOT SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$1.04-8.7% Next Q
Q2 (-2Q)
24
Grade E$0.95-1.1% Next Q
Q3 (-1Q)
26
Grade E$0.94+10.6% Next Q
Current
29
Grade E$1.04-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MBOT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MBOT currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.24) and Max Pain ($1.09) forces dealer call-delta covering toward $3.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBOT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBOT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $1$1.04H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MBOT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-15.8% ROIC with 42.0% gross margin and -17.42% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

8/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like MBOT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBOT)

  • ✓Walkthrough of MBOT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MBOT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.71%▼ DESCENDING CHANNEL
2026-11-03O $1.12H $1.12L $1.04C $1.04VOL 1.33M
RES: $1.68SUP: $0.78SMA50: $1.24SMA200: $1.84
$2.66$2.19$1.72$1.25$0.78RES $1.68SUP $0.78$1.042026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBOT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBOT Butterfly Map → + Track MBOT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +26.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MBOT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBOT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBOT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBOT)

Health Care Rank #838 of 1015 ⚔️ LNSR vs MBOT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBOT vs. LNSR, QTEX, LUCD, SKIN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Microbot Medical Inc. (MBOT) ranks #838 by composite RQD confidence (29/100, grade E) and #692 by equity capitalization ($73.2M). Within this direct 5-issuer industry benchmark cohort, MBOT leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. LUCD currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with MBOT at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MBOT ACTIVE
Microbot Medical Inc.
E 29/100 — — -15.8% -4.59% $73.2M Benchmark Subject
LNSR
LENSAR Inc.
E 18/100 — 39.4% -35.0% -2.91% $71.7M /lnsr-vs-mbot →
QTEX
QTREX Quantum Ltd.
D- 36/100 — 0.7% -35.0% -8.20% $68.3M /qtex-vs-mbot →
LUCD
Lucid Diagnostics Inc.
D- 39/100 — — -35.0% +0.37% $82.3M /lucd-vs-mbot →
SKIN
SkinHealth Systems Inc. (Class A)
E 32/100 — 65.3% -26.9% +4.43% $64.7M /skin-vs-mbot →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883975 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Microbot Medical Inc. (MBOT) reported GAAP revenue of $41.3M (+26.8% vs. FY2024 revenue of $32.5M , and +49.6% cumulative change since FY2023) , GAAP net income of -$13.1M, operating cash flow of -$13.0M, and free cash flow of -$13.1M (-48.1% YoY). On the balance sheet, MBOT closed FY2025 with $81.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $41.3M -$13.1M -$13.0M -$13.1M $81.5M —
FY2024 (FY) 2024-12-31 $32.5M -$11.4M -$8.8M -$8.9M $6.0M —
FY2023 (FY) 2023-12-31 $27.6M -$10.7M -$8.5M -$8.5M — —

3. MBOT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Microbot Medical Inc. (NASDAQ: MBOT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.04 (-4.59% 1D, market cap $73.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MBOT ranks #838 in composite RQD confidence.

How does MBOT compare to LNSR and QTEX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, LNSR (LENSAR Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $71.7M) and QTEX (QTREX Quantum Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MBOT?

Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $41.3M in revenue (+26.8% YoY), -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MBOT trading relative to its 50-day, 200-day, and 52-week technical levels?

MBOT last traded at $1.04 (-4.59% on volume of 1,082,077 shares), positioning the stock -16.13% below its 50-day simple moving average ($1.24) and -43.48% below its 200-day simple moving average ($1.84). Across its 52-week range of $0.93 to $2.86, MBOT sits at the 5.7% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.17).

Direct Sub-Reports: MBOT RQD Cockpit MBOT 12M Forecast MBOT Earnings & Move MBOT Dividends & DRIP MBOT Insiders & 13F MBOT Whale Options MBOT Profit Sankey MBOT News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

MBOT — Microbot Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Microbot Medical Inc. (MBOT) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.04 (-4.59% 1D, market capitalization $73.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -15.8%, gross margin of —, operating margin of —, and free cash flow yield of -17.42%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Microbot Medical Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. It operates with a market capitalization the profile rounds to $0.1B. Specific product lines, customer segments, and revenue model details are — The financials report — revenue across the three reported fiscal years.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Microbot Medical Inc. (MBOT) reported $41.3M in annual revenue (up from $32.5M in FY2024, +26.8% YoY) and -$13.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($27.6M revenue, -$10.7M net income) through FY2025, MBOT scaled operating cash flow to -$13.0M and free cash flow to -$13.1M, backed by $81.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.42% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.93 – $2.86 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), MBOT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MBOT sustain or expand its — operating margin and -15.8% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $41.3M and free cash flow of -$13.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MBOT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MBOT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Microbot Medical Inc. (MBOT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MBOT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MBOT Bull vs. Bear Conversation Board — What's Your Call at $1.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBOT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MBOT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.31 (+20.2%)
📌 Pinned Debate

Whale 13F flow scores 10 / 20, the strongest pillar, indicating institutional accumulation and options positioning.

Long MBOT at $1.09 targeting $1.31. Whale 13F flow scores 10 / 20, the strongest pillar, indicating institutional accumulation and options positioning.. Institutional whale score is 5/20 and the risk/reward vs. the $0.93 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.09 and keeping dry powder in case we test $1.01.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.90 (-17.4%)
Spot @ $1.09

Negative ROIC of -15.8% and FCF yield of -17.42% show the business is not currently generating returns on capital or free cash.

I respect the product at Microbot Medical Inc., but the stock at $1.09 is a different story. Negative ROIC of -15.8% and FCF yield of -17.42% show the business is not currently generating returns on capital or free cash.. FCF yield is -17.42% and RQD sits at 29/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%